Addario Lung Cancer Medical Institute (ALCMI)

New Device May Deliver Faster Lung Cancer Results and Diagnoses | CURE This device detects and characterizes lesions on low-dose CT scans, helping patients with cancer get faster, tailored care and avoid unnecessary procedures.

Median Technologies' Eyonis LCS has received FDA 510(k) clearance as the first AI-based device for both detecting and diagnosing lung cancer in low-dose CT scans. #lungcancer
www.curetoday.com/view/new-dev...

ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin Abstract. Small cell lung cancer (SCLC) is a recalcitrant thoracic malignancy known for acquired chemoresistance, early metastatic spread, and poor overall survival. Lurbinectedin, a DNA minor groove…

Congratulations to Misty Shields and colleagues at the Indiana University School of Medicine and Moffitt Cancer Center! #lungcancer
aacrjournals.org/mct/article-...

Client Challenge Please enable JavaScript to proceed.

Must-read insights from our good friend Dr. Jorge Nieva from USC Norris Comprehensive Cancer Center! #lungcancer
www.hmpgloballearningnetwork.com/site/jcp/int...

Proximity to nuclear power plants associated with increased cancer mortality | Harvard T.H. Chan School of Public Health U.S. counties located closer to operational nuclear power plants have higher rates of cancer mortality than those located farther away, according to a new Harvard Chan School study.

A comprehensive national study led by Harvard T.H. Chan School of Public Health found that U.S. counties located closer to operational nuclear power plants experience higher cancer mortality rates than those farther away. #lungcancer
hsph.harvard.edu/news/proximi...

Cancer Stress Protein Helps Tumors Hide From Immunity /PRNewswire/ -- A protein made by stressed cancer cells helps lung and pancreatic tumors evade the immune system, a new study shows. Led by researchers from...

Congrats to ALCMI consortium member NYU Langone Health! Researchers there have discovered that lipocalin 2 (LCN2) enables lung and pancreatic tumors to evade immune attack by manipulating immune cells in the tumor microenvironment. #lungcancer

Inhaled microplastics linked to lung cancer, asthma and fibrosis - AirQualityNews Microplastics in the air are infiltrating human lungs, triggering oxidative stress, inflammation and cellular damage that may contribute to a range of serious respiratory diseases, a comprehensive…

Microplastics may be emerging as a serious danger to lung health. #lungcancer
airqualitynews.com/headlines/in...

Mayo Clinic study identifies mechanism behind immunotherapy resistance in lung cancer The study, published in Cancer Immunology Research, focuses on regulatory T cells, immune cells that normally keep the immune system from becoming overactive.

Whoa! Mayo Clinic researchers led by Henrique Borges da Silva, Ph.D., have uncovered how lung tumors exploit regulatory T cells via P2RX7 to evade immunotherapy. #lungcancer
newsnetwork.mayoclinic.org/discussion/m...

Hypofractionation is ‘Excellent Tool’ in Radiotherapy for Lung Cancer | CancerNetwork Pranshu Mohindra, MD, outlined considerations for optimizing the use of hypofractionated radiation for patients with lung cancer.

Pranshu Mohindra, MD, MMM, from University Hospitals Cleveland Medical Center Inc., presents a compelling case for expanding the use of hypofractionated radiotherapy in lung cancer treatment. #lungcancer
www.cancernetwork.com/view/hypofra...

Congratulations to Johnson & Johnson! The FDA has approved RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy with monthly subcutaneous dosing for first-line EGFR-mutated advanced NSCLC. #lungcancer
www.jnj.com/media-center...

Atezolizumab Plus Concurrent Chemoradiation Fails to Improve Survival in LS-SCLC | OncLive Data from the phase 3 LU005 trial found no OS benefit and high immune-related toxicity with concurrent/adjuvant atezolizumab and chemoradiation in LS-SCLC.

The NRG ONCOLOGY/Alliance Healthcare LU005 trial shows that concurrent and adjuvant atezolizumab added to chemoradiation does not improve overall survival in limited-stage small cell lung cancer, as published in the Journal of Clinical Oncology. #lungcancer

Epithelial Injury Biomarkers Linked to Lung Abnormalities After COVID-19 Injury and scarring markers are seen in association with RLA on follow-up CT following recovery from COVID-19.

New news on COVID-19 and lung cancer. Imperial College London researchers have uncovered epithelial injury biomarkers that predict residual lung abnormalities in COVID-19 survivors, as detailed in a new eBioMedicine study led by Iain Stewart, Ph.D. #lungcancer

Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases - Cancer Gene Therapy Cancer Gene Therapy - Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases

A new review from Debanjan Bhattacharya, PhD, Benjamin Roman, and Sanjana Reddy in Cancer Gene Therapy provides a clear picture of how next‑generation KRASG12C inhibitors are shaping the future of intracranial disease control in NSCLC. #lungcancer
www.nature.com/articles/s41...

FDA Grants RMAT Designation to HSV-Based Immunotherapy in NSCLC | CancerNetwork Early data from the KYANITE-1 study support the RMAT designation for KB707 as a treatment for those with advanced or metastatic NSCLC.

The FDA has granted RMAT designation to KB707, an inhaled replication-defective HSV-1 immunotherapy from Krystal Biotech, Inc., supported by early efficacy signals from the phase 1/2 KYANITE-1 study. #lungcancer
www.cancernetwork.com/view/fda-gra...

Local Consolidative Therapy in EGFR-Mutant NSCLC: Selecting the Right Patient at the Right Time The phase 2 NORTHSTAR trial has demonstrated an EGFR-specific benefit of local consolidative therapy (LCT) in stage IV <i>EGFR</i>-mutant non–small cell lung cancer treated with osimertinib, with an…

The NORTHSTAR trial has established a significant EGFR-specific benefit for local consolidative therapy in stage IV EGFR-mutant NSCLC, demonstrating an 8-month improvement in progression-free survival when added to osimertinib. #lungcancer
dailynews.ascopubs.org/do/local-con...

At ALCMI, our hearts are in the research. This Valentine’s Day, we celebrate the incredible patients, families, and researchers who inspire us every day. #lungcancer

Kras G12C– and G12D–driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models KRAS G12D and G12C produce lung tumors with distinct microenvironmental and growth features that influence progression and survival.

KRAS allele identity dictates the fundamental biology of lung cancer, as William Hai-Cheng Huang MD, and colleagues demonstrate that G12C and G12D mutations diverge in oncogenic potency, immune engagement, and relapse kinetics. #lungcancer
www.science.org/doi/10.1126/...

Classification and Management of Ischemic Stroke in Patients With Active Cancer: A Scientific Statement From the American Heart Association | Stroke About 10% to 15% of patients with ischemic stroke have a history of cancer, half of whom have active malignancy at the time of stroke. With improved cancer treatments extending patient survival, the…

Metastatic lung cancer and adenocarcinoma histology are among the strongest predictors of acute ischemic stroke, according to a new American Heart Association scientific statement that defines cancer-related stroke as a distinct, high-risk clinical entity. #lungcancer

Summit’s Potential Keytruda Rival Gets November FDA Decision Date The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.

Save the date! Summit Therapeutics, Inc.s’ PD-1/VEGF bispecific ivonescimab now has an FDA decision date of November 14 for EGFR-mutant, locally advanced or metastatic non-squamous NSCLC. #lungcancer
www.biospace.com/fda/summits-...

Treating Lung Cancer Patients Earlier in Day Improves Outcomes Research shows that people with advanced lung cancer can benefit from having immunochemotherapy treatment before 3pm.

New research shows that timing first-line chemo-immunotherapy earlier in the day significantly improves survival outcomes for patients with advanced non-small cell lung cancer. #lungcancer
www.insideprecisionmedicine.com/topics/oncol...

Zenocutuzumab, the first-in-class HER2/HER3 bispecific, has shown durable responses and meaningful progression-free survival in the phase 2 eNRGy trial for NRG1 fusion–positive advanced NSCLC. #lungcancer
www.oncologynewscentral.com/nsclc/first-...

Demystifying a new tool for early lung cancer detection Bayhealth’s mobile classroom lets students and neighbors explore Ion robotic bronchoscopy, boosting awareness, screening and career interest.

Kudos to the American Medical Association for shining a light on an innovative approach to lung cancer detection and treatment! #lungcancer
www.ama-assn.org/public-healt...

Lung cancer survivors at risk for non-lung secondary cancer years after definitive therapy Survivors of non-small cell lung cancer are at risk for both second primary lung cancers as well as non-lung secondary malignancies years after definitive local therapy.A retrospective evaluation of…

Lung cancer survivors face a meaningful long‑term risk of non‑lung secondary cancers years after curative therapy, according to new data. #lungcancer
www.healio.com/news/hematol...

Today, we recognize #WorldCancerDay, and we recommit to our mission to make lung cancer a survivable disease. Have an idea for a clinical trial? Let's talk and get to work! #lungcancer

Oncogenic p53 induces mitotic errors in lung cancer cells by recopying DNA replication forks conferring targetable proliferation advantage - Cell Death & Differentiation Cell Death & Differentiation - Oncogenic p53 induces mitotic errors in lung cancer cells by recopying DNA replication forks conferring targetable proliferation advantage

Oncogenic p53 in lung cancer does more than disrupt genome integrity. A new study shows that mutant, gain-of-function p53 actively drives a replication-based loop that both accelerates tumor growth and creates a targetable vulnerability. #lungcancer
www.nature.com/articles/s41...

The American College of Radiology, the American Society for Radiation Oncology (ASTRO), and The Society of Thoracic Surgeons have issued a rare joint statement to correct "misinformation" and methodological flaws that distort the perceived risks of lung cancer screening. #lungcancer

Bristol Myers Squibb and Microsoft Partner to Advance AI-Driven Early Lung Cancer Detection - OncoDaily Bristol Myers Squibb and Microsoft Partner to Advance AI-Driven Early Lung Cancer Detection / AI in healthcare, AI in Radiology, Artificial Intelligence in

New partnership alert! Bristol Myers Squibb and Microsoft have formed a new strategic partnership to use FDA-cleared radiology AI to detect lung cancer earlier and at scale. #lungcancer
oncodaily.com/techology/br...

Cancer Center investigator targets key enzyme complex to treat KRAS-mutated lung cancer The University of Cincinnati Cancer Center’s Tom Cunningham has received a two-year, $150,000 grant from the Lung Cancer Research Foundation (LCRF) to test approaches to neutralize an enzyme complex...

Tom Cunningham, PhD, at the University of Cincinnati Cancer Center, is targeting the PRPS enzyme complex as a therapeutic dependency in KRAS-mutated lung cancer, backed by a two-year, $150,000 Lung Cancer Research Foundation grant. #lungcancer
www.uc.edu/news/article...

Associations between Prior Lung Diseases and Risk of Lung Cancer in Populations With No Smoking History: A Systematic Review and Meta-Analysis - PubMed History of TB and CB were associated with increased lung cancer risk among populations with no smoking history. Future studies examining these associations should analyze more diverse populations and...

A history of tuberculosis and chronic bronchitis increases lung cancer risk in people who have never smoked, according to a new systematic review. #lungcancer
pubmed.ncbi.nlm.nih.gov/41534708/

Gut bacteria molecule boosts lung cancer treatment response - UF Health GAINESVILLE, Fla. — UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to…

Christian Jobin, Ph.D., and Rachel Newsome, Ph.D., at UF Health Cancer Institute have identified a gut microbiota–derived metabolite, Bac429, that materially increases immunotherapy activity in lung cancer models and is now being advanced into a drug candidate. #lungcancer

New Research May Reveal Why Lung Cancer and COPD Overlap Dr. Catherine Sears’ research seeks to change the way COPD and lung cancer are treated.

Catherine Sears, MD, and colleagues at Indiana University are linking impaired DNA repair to the shared biology of emphysema and lung cancer. #lungcancer
www.lung.org/blog/copd-lu...